Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

Abstract Metronomic therapy has been gaining importance in the neoadjuvant setting of breast cancer treatment. Its clinical benefits may involve antiangiogenic machinery. Cancer cells induce angiogenesis to support tumor growth by secreting factors, such as vascular endothelial growth factor (VEGF)....

Full description

Bibliographic Details
Main Authors: Roberto J. Arai, Vanessa Petry, Paulo M. Hoff, Max S. Mano
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Biomarker Research
Subjects:
Metronomic chemotherapy
Angiogenesis
Biomarker
Neoadjuvant
Breast cancer
Online Access:http://link.springer.com/article/10.1186/s40364-018-0135-x

Internet

http://link.springer.com/article/10.1186/s40364-018-0135-x

Similar Items